Prostate-specific antigen or human kallikrein 3? Recent developments.
作者信息
Diamandis E P
机构信息
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, University of Toronto, Ont., Canada.
出版信息
Tumour Biol. 1998;19(2):65-7; discussion 67-8. doi: 10.1159/000029976.
PMID:9486557
Abstract
摘要
相似文献
1
Prostate-specific antigen or human kallikrein 3? Recent developments.
Tumour Biol. 1998;19(2):65-7; discussion 67-8. doi: 10.1159/000029976.
2
Prostate detection possibility.
JAMA. 1999;281(24):2274-5.
3
[Prostate Specific Antigen (PSA), yet how much damage?].[前列腺特异性抗原（PSA），但会造成多大损害？]
Presse Med. 2012 May;41(5):482-5. doi: 10.1016/j.lpm.2011.12.011. Epub 2012 Feb 14.
4
Value of a Statistical Model Based on Four Kallikrein Markers in Blood, Commercially Available as 4Kscore, in All Reasonable Prostate Biopsy Subgroups.基于血液中四种激肽释放酶标志物（商品名为4Kscore）的统计模型在所有合理的前列腺活检亚组中的价值。
Eur Urol. 2018 Oct;74(4):535-536. doi: 10.1016/j.eururo.2018.05.032. Epub 2018 Jun 11.
5
Prostate-specific antigen (hK3) and human prostatic glandular kallikrein (hK2) in the detection of early stage human prostate cancer.前列腺特异性抗原（hK3）和人前列腺腺激肽释放酶（hK2）在早期人类前列腺癌检测中的应用
J Lab Clin Med. 1998 Apr;131(4):298-9. doi: 10.1016/s0022-2143(98)90178-0.
6
4-Kallikrein Test and Kallikrein Markers in Prostate Cancer Screening.4-激肽释放酶检测及激肽释放酶标志物在前列腺癌筛查中的应用
Urol Clin North Am. 2016 Feb;43(1):39-46. doi: 10.1016/j.ucl.2015.08.004.
7
Sarcomatoid carcinoma of the prostate with adenocarcinoma, squamous cell carcinoma, and heterologous components.前列腺肉瘤样癌伴腺癌、鳞状细胞癌及异源性成分。
APMIS. 2016 Aug;124(8):719-22. doi: 10.1111/apm.12548. Epub 2016 May 20.
8
Prostate Health Index (PHI): golden bullet or just another prostate cancer marker?前列腺健康指数（PHI）：是万灵药还是只是另一种前列腺癌标志物？
Eur Urol. 2013 Jun;63(6):995-6; discussion 996-7. doi: 10.1016/j.eururo.2013.02.004. Epub 2013 Feb 14.
9
Prostate carcinoma: clarification through clinical insight and molecular diagnostics.前列腺癌：通过临床洞察和分子诊断加以阐明
West J Med. 1998 Jun;168(6):525.
10
Re: The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.回复：游离前列腺特异性抗原与总前列腺特异性抗原的百分比、PCA3以及激肽释放酶检测指标对欧洲前列腺癌筛查随机对照试验（ERSPC）中前列腺癌预筛查男性风险计算器的附加价值。
J Urol. 2015 Jan;193(1):127. doi: 10.1016/j.juro.2014.10.074. Epub 2014 Oct 22.
Zotero 插件